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Duplicate Staphylococcus aureus isolates were analyzed to determine the impact of multiple isolates from the
same patient on annual antibiogram data. During a 6-year period (1996 to 2001), 3,227 patients with 4,844 S.
aureus isolates were evaluated. A total of 39% of patients with methicillin-resistant S. aureus (MRSA) (n  860)
and 23% of patients with methicillin-susceptible S. aureus (MSSA) (n  2,367) infections had duplicate
isolates. Cumulative data show that 91% of the patients during this 6-year period with duplicate isolates (2 to
13 duplicates/year) did not switch between MSSA and MRSA but retained the original S. aureus strain whether
it was MSSA or MRSA. Rates of MRSA were calculated for each year by using all isolates and then eliminating
duplicates. The impact of duplicate MRSA and MSSA isolates was evaluated by using the ratio of isolates per
patient such that ratios of >1.0 indicate >1 isolate per patient. The 6-year ratio for MRSA was 1.90
isolates/patient, and the ratio for MSSA was 1.35. A significant difference (P < 0.05) was noted in the MRSA
rates in 4 of 6 years when duplicate isolates were removed. Common phenotypic antibiogram patterns were
compared for all MRSA isolates during the 6-year period, and 64% were of a single antibiogram phenotype.
Eighty-eight percent of patients with duplicate MRSA isolates had phenotypically identical multiple isolates.
The rate of MRSA differs when duplicate isolates are removed from the antibiogram data.
Staphylococcus aureus is a common cause of serious infec-
tions in the hospital and the community. Methicillin-resistant
S. aureus (MRSA) was first detected in the1960s, and since that
time it has spread rapidly worldwide, becoming a leading cause
of nosocomial infections (5, 7, 15, 16). Currently in the United
States, 50% of nosocomial S. aureus infections in intensive
care units (ICUs) are due to MRSA (6, 13). An additional
concern with MRSA is that many strains have acquired resis-
tance to several classes of antibiotics (3, 11).
The periodic evaluation of rates for MRSA is crucial to both
infection control monitoring and decisions regarding empirical
therapy. A common method of documenting and monitoring
MRSA rates is the antibiogram that reports periodically the
rate of antimicrobial susceptibility for each bacterial organism
and antibiotic. Generally, an antibiogram is a cumulative pro-
file of antimicrobial susceptibility results for a given time pe-
riod (10, 12). When properly prepared, antibiograms are im-
portant sources of information for healthcare providers. The
lack of standardization in the preparation and data assimila-
tion of hospital antibiograms has not been addressed until
recently. To assist institutions, the National Committee for
Clinical Laboratory Standards (NCCLS) organization has ap-
proved guidelines in the last year that are published in a doc-
ument (M39A) entitled Analysis and Presentation of Cumula-
tive Antimicrobial Susceptibility Test Data: Approved Guideline
(12). This document addresses the issue of repeat isolates and
makes recommendations that repeat isolates should be elimi-
nated or reduced to more accurately reflect antimicrobial re-
sistance trends.
The present study has analyzed the number of duplicate
isolates of S. aureus from the same patient and determined the
impact of these repeat isolates on the annual rate of MRSA
over a 6-year period. Duplicate isolates of MRSA were ana-
lyzed for changes in the antibiogram phenotype during the
6-year period. The results of this analysis led to an adjustment
in laboratory practice for testing S. aureus for antimicrobial
susceptibility that resulted in a cost reduction for the labora-
tory and a more accurate reflection of MRSA rates.
MATERIALS AND METHODS
Susceptibility testing. All S. aureus isolates were tested with the Vitek system
using the GPS-106 card for the years 1999 through 2001 and GPS-101 for the
years 1996 through 1998. A repeat isolate of S. aureus from the same patient
obtained within 7 days was not tested for antimicrobial susceptibility and is not
included in this analysis. Isolates of S. aureus, including MRSA, identified for
surveillance purposes only, were not included in the analysis since they were
coded and tested by different methods. Isolates of MRSA or MSSA from out-
patient locations were not included in this analysis to reflect the rate of methi-
cillin resistance within the hospital units.
Data analysis. The susceptibility data were extracted from the laboratory
information system (MISYS) and transferred into a Microsoft Access data-
base. A report was created in MISYS Cache SQL by using function RDB to
transfer the data to result tables. Selected fields were specified by using the
MCRES_VIEW to gather data on S. aureus cultures from MISYS. The fields
specified were date of admission, date of culture, source of culture, location of
* Corresponding author. Mailing address: The University of Kansas
Medical Center, Department of Pathology and Laboratory Medicine,
3901 Rainbow Blvd., Kansas City, KS 66160. Phone: (913) 588-1753.
Fax: (913) 588-1777. E-mail: rhorvat@kumc.edu.
4611
patient in the hospital, patient identification number, unique laboratory acces-
sion number, and the results of all antimicrobial agents that were tested for each
isolate. These data were then transferred to the Microsoft Access database,
which allowed for more detailed grouping and sorting of the antibiotic results.
Analysis for rates of MRSA was calculated for a 6-year period between 1996 and
2001. Comparisons were made between the rates of MRSA noted in all hospital
units versus the rates of MRSA reported from ICUs or non-ICUs. Some patients
were hospitalized both in the ICUs and in non-ICU locations during a single
hospital stay; thus, the patient and isolates were designated based on the units
where the first MRSA or MSSA was isolated. The chi-square test was used to
determine the statistical significance of repeat isolates on annual susceptibility
rates.
Phenotypic analysis. Common phenotypic antibiogram patterns of MRSA
were examined and compared cumulatively for the 6-year period. When we
evaluated phenotypes, isolates exhibiting intermediate resistance to antimicro-
bial agents were considered resistant. The most common phenotype of MRSA
was designated the major phenotype, while the remaining minor phenotypes
were given numbered designations (types 2 to 7).
RESULTS
We examined 4,844 S. aureus isolates from 3,227 patients in
a university hospital over a 6-year period from 1996 to 2001.
Cumulative data for this 6-year period showed that 879 pa-
tients had duplicate isolates during the 6-year antibiogram
period. The majority (91%) of patients with duplicate S. aureus
isolates had multiple isolates that were all MRSA or MSSA.
During this 6-year period, 6% of patients (n  56) originally
presented with an MSSA and then had an MRSA isolated.
This calculates to 10 patients per year. This change from
MSSA to MRSA occurred during the same hospital admission
in 27 patients (48%), with an average time between isolates of
2.5 weeks (range, 1 to 4 weeks). Twenty-nine patients (52%)
changed from MSSA to MRSA isolates during different hos-
pital admissions, with an average time between isolates of 2.5
months (range, 1 to 40 weeks). Interestingly, during the 6 years
a few patients (n  16) originally presented with an MRSA and
subsequently had an MSSA strain isolated. The majority of
these patients (76%) changed from an MRSA to an MSSA
during different hospital admissions, with the average time
between isolates of 5.6 months (range, 2 to 40 weeks). The
majority of patients with duplicate isolates had either all
MRSA or MSSA isolates, and the impact of these duplicate
isolates was analyzed for each year (Table 1).
In Table 1, the numbers of MRSA and MSSA isolates and
patients are divided by hospital location, such as ICUs, non-
ICUs, and all hospital units, for each individual year studied.
The data were evaluated as the ratio of isolates per patient in
a 1-year period as described by Stelling (J. M. Stelling, Abstr.
42nd Intersci. Conf. Antimicrob. Agents Chemother., abstr.
394, 2002). For example, a ratio of 1.0 indicated one isolate for
each patient during a 1-year period. This allows for the analysis
and standardization of the number of isolates per patient. The
average ratio of MRSA isolates per patient for all years and all
TABLE 1. Analysis of MRSA and MSSA ratio of isolates per patient from 1996 to 2001
Yr and
strain type







Patients Isolates Patients Isolates Patients Isolates
1996
MRSA 144 298 2.07 42 94 2.24 102 204 2.00
MSSA 450 631 1.40 79 114 1.44 371 517 1.39
1997
MRSA 133 269 2.02 38 86 2.26 95 183 1.93
MSSA 455 613 1.35 81 120 1.48 374 493 1.32
1998
MRSA 143 236 1.65 48 76 1.58 95 160 1.68
MSSA 424 589 1.39 70 97 1.39 354 492 1.39
1999
MRSA 136 248 1.82 37 66 1.78 99 182 1.84
MSSA 391 515 1.32 53 78 1.47 338 437 1.29
2000
MRSA 112 195 1.74 29 53 1.83 83 142 1.71
MSSA 257 345 1.34 55 72 1.31 202 273 1.35
2001
MRSA 192 391 2.04 47 105 2.23 145 286 1.97
MSSA 390 514 1.32 52 83 1.60 338 431 1.26
All years
MRSA 860 1,637 1.90 241 480 1.99 619 1,157 1.87
MSSA 2,367 3,207 1.35 390 564 1.45 1,977 2,643 1.34
a Analysis of patients with S. aureus (both MRSA and MSSA) from all units in the hospital, including ICUs but not including outpatient clinics or 1-day surgery.
b Analysis of patients with S. aureus (both MRSA and MSSA) infection only from ICUs that included surgical ICUs, medical or trauma ICUs, burn units, pediatric
ICUs, and neonatal ICUs.
c Analysis of patients with S. aureus (both MRSA and MSSA) from all units in the hospital, excluding the ICUs listed in columns 5 to 7.
d The ratio expressed is the number of isolates detected divided by the number of patients during the analysis period.
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hospital units was 1.90 (range, 1.65 to 2.07) versus the average
ratio for MSSA of 1.35 (range, 1.32 to 1.40) (Table 1). The
average ratio of MRSA in ICUs for all 6 years was 1.99 (range,
1.58 to 2.26), while the average ratio of MSSA in ICUs was
1.45 (range, 1.31 to 1.60). Similar ratios were noted for non-
ICUs over the 6 years. The higher number of duplicate isolates
from patients with MRSA significantly impacted the overall
hospital susceptibility rates reported for 4 of 6 years (P  0.05)
(Fig. 1A). Interestingly, when we analyzed data from ICUs
only, we found that duplicate MRSA isolates increased the
MRSA annual susceptibility rates but that this increase was not
statistically significant for any single year (P  0.06 to 0.99)
(Fig. 1B). However, when we evaluated the total from 6 years
of ICU data, the MRSA rates were significantly different (P 
0.002) if the values for the duplicate isolates of MRSA and
MSSA were removed. In non-ICU hospital units, the annual
susceptibility rate was increased each year due to duplicate
MRSA isolates, and in 4 of 6 years this increase was significant
(P  0.05) (Fig. 1C).
Several patients with MRSA had as many as 13 duplicate
isolates of MRSA within a 1-year period (data not shown).
Sixty-two patients during the 6-year period had 5 MRSA
isolates (range, 5 to 13) in any 1-year period. Of these 62
patients, 14 (23%) were located in an ICU. Thirty-five patients
had 5 isolates of MSSA (range, 5 to 12) within a 1-year
period. Seven (20%) of these patients with duplicate MSSA
isolates were in an ICU.
Table 2 shows a comparison of the antibiogram phenotypes
for all of the MRSA isolates obtained during the 6-year period,
including duplicate isolates. The majority of the MRSA iso-
lates (64%) had the same antibiogram phenotype, and this
phenotype was designated the major phenotype. The other
common MRSA phenotypes are shown in Table 2 as types 2
through 7 and are designated minor phenotypes. Phenotype 2
(8% of all MRSA types) was similar to the major type except
for its resistance to gentamicin and trimethoprim-sulfamethox-
azole (Table 2, boldface). Phenotype 3 comprised 7% of all the
MRSA isolates, and this phenotype varied from the major
phenotype in that it was resistant to gentamicin. Phenotype 4
comprised 5% of the total MRSA and varied from the major
type in that it was susceptible to clindamycin. Phenotypes 5 and
6 each accounted for 3% of the total MRSA isolates. Pheno-
type 5 varied from the major type by exhibiting susceptibility to
clindamycin and levofloxacin-ciprofloxacin. Phenotype 6 was
similar to the major type except for resistance to tetracycline.
Phenotype 7 was susceptible to all of the antimicrobial agents
tested except oxacillin and made up 2% of all the MRSA.
There were 26 other phenotypes that varied from the pheno-
types listed in Table 2, and each consisted of 1% of the total
MRSA isolates during a 6-year period. Of these 26 unusual
phenotypes, 12 were isolated only once or from only one pa-
tient during the 6 years.
FIG. 1. MRSA detection rates. Bars: u, rate of MRSA with dupli-
cate isolates included; , recalculated rates after all duplicate isolates
are removed. P values were calculated by chi-square analysis. A P value
of 0.05 is considered significant and is indicated by an asterisk.
TABLE 2. Common antibiogram phenotypes of MRSA





Phenotype for antimicrobial agenta:
ERY CLI GEN LEV-CIPb OXA RIF SXT TET VAN
Major type 64 R R S R R S S S S
Type 2 8 R R R R R S R S S
Type 3 7 R R R R R S S S S
Type 4 5 R S S R R S S S S
Type 5 3 R S S S R S S S S
Type 6 3 R R S R R S S R S
Type 7 2 S S S S R S S S S
a All isolates were tested by using the Vitek system. ERY, erythromycin; CLI,
clindamycin; GEN, gentamicin; LEV-CIP, levofloxacin-ciprofloxacin; OXA, ox-
acillin; RIF, rifampin; SXT, trimethoprim-sulfamethoxazole; TET, tetracycline;
VAN, vancomycin. Phenotypes were determined by comparing the results of
each antimicrobial susceptibility for the 6-year period. Isolates with intermediate
results were considered resistant. Differences from the major phenotype are
indicated in boldface.
b Ciprofloxacin was tested for the years 1996 to 1998, and levofloxacin was
tested for the years 1999 to 2001.
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Figure 2 shows that 295 of 335 (88%) patients with duplicate
MRSA isolates had the same antibiogram type in each repeat
isolate during a 6-year period. Of 40 patients, 37 (93%) with
different MRSA phenotypes among the duplicate isolates had
only a single isolate that differed from the other duplicates.
The patients with different duplicate isolates tended to have
more isolates per patient with a ratio of 4.42, whereas the ratio
of isolate to patient in the group with identical duplicate
MRSA isolates was 3.19.
Based on these results, the testing of multiple MRSA iso-
lates from the same patient was abbreviated by modifying the
protocol used to detect duplicate MRSA. For a 90-day period
repeat S. aureus isolates from known MRSA patients were
flagged by the laboratory computer and were not tested using
the Vitek ($2.50 per card) but were screened only for suscep-
tibility to oxacillin and vancomycin by using antibiotic agar
screen plates ($0.20 each). Upon the request by the attending
physician, any MRSA isolate during this period would be fully
tested on the Vitek. After 90 days the S. aureus isolates were
retested with the Vitek. This modification in protocol was
designed in conjunction with the medical staff and was vali-
dated for 90 days before implementation. This screening only
applied to patients infected with MRSA. All patients with
MSSA had duplicate isolates tested by using the Vitek to
detect the MRSA. This change reduced the cost associated
with testing duplicate isolates by $1,200 annually due to de-
creased labor and material costs. In addition, this practice
reduced the impact of duplicate MRSA isolates on the calcu-
lated rate of MRSA. Screened results are coded differently and
not included into the annual antibiogram data by the labora-
tory computer. Since we have implemented this change (1.5
years), there have been no requests by clinicians for testing the
duplicate MRSA with the Vitek. The first year of this practice
resulted in a ratio of MRSA isolate(s) per patient of 1.41, a
result similar to the ratio of MSSA isolates per patient (1.32).
During this year the calculated rate of MRSA with duplicates
was 39%, which was not significantly different (P  0.99) than
the MRSA rate without duplicates (37%). Thus, it seems that
adoption of this screening protocol for duplicate MRSA within
a 90-day period diminished the impact of the duplicate MRSA
on the calculated susceptibility rates.
DISCUSSION
Numerous factors influence MRSA rates within an institu-
tion. Comorbidities, advanced age, and the number of invasive
procedures are associated with acquiring MRSA (8, 18). The
transfer of an infected patient from a different institution can
introduce MRSA into a hospital. At other times, MRSA is
spread from patient to patient or selected out by use of anti-
microbials (2, 17, 20, 22). Several studies have shown that
MRSA infections cost more than MSSA infections (1, 14, 17).
Infections with MRSA are linked with an excess length of
hospital stay (14). Nosocomial bloodstream infections and
mortality associated with S. aureus pneumonia was noted to be
greater when patients were infected with MRSA (4, 17). Insti-
tutions have become concerned with ensuring that the rate of
MRSA is accurate because of the morbidity, mortality, and
cost associated with MRSA infections. Assessing and correct-
ing the data for duplicate isolates will reduce the calculated
rate of MRSA and allow institutions to more accurately eval-
uate the impact of MRSA.
We performed a retrospective analysis of S. aureus isolates
tested for antimicrobial susceptibility during a 6-year period to
determine the impact of duplicate isolates on the annual rate
of MRSA. These data showed that multiple repeat isolates of
MRSA from the same patient are more frequent than multiple
repeat isolates of MSSA in each year of a 6-year period. Of a
total of 860 patients infected with MRSA, 335 (39%) had one
or more duplicate isolates (Table 1), resulting in an average
isolate to patient ratio of 1.90 for the 6-year period. In contrast,
during the same time period duplicate isolates of MSSA were
cultured from the same patient (n  2,367) 23% of the time,
with an average isolate/patient ratio of 1.35. These data show
that the overall annual rate of MRSA can differ when duplicate
isolates are used in calculating antibiogram data. A significant
difference was noted in MRSA rates (P  0.05) in 4 of 6 years
when we evaluated data with or without duplicate isolates from
all hospital units (Fig. 1). When duplicate MRSA isolates from
patients in the ICUs were removed, there was a small decrease
in annual MRSA rates. This difference was not statistically
significant for individual years due to the small number of
isolates and patients in the ICU compared to the number in all
hospital units. When we evaluated cumulative data from all 6
years of the study, the ICU rates were significantly (P  0.002)
altered if duplicate S. aureus isolates were removed.
Of interest was the finding that 64% of all the MRSA iso-
lates, including both duplicates and nonduplicates, during this
period had the same antibiogram phenotype (Table 2). Over
the 6-year period there was no change in the most common
MRSA phenotype. There were a few additional MRSA phe-
notypes identified but each of the other types comprised 10%
of the total and, as a result, impact the annual antibiogram
susceptibility rates minimally. In addition, the majority of pa-
tients (88%) with duplicate MRSA isolates had multiple iso-
lates with identical phenotypic antibiograms (Fig. 2). These
duplicate isolates from the same patient consisted of both a
major phenotype or most-common phenotype and several mi-
nor phenotypes or less-prevalent phenotypes. One reason for
duplicate testing of bacterial isolates from the same patient is
to monitor for the development of antimicrobial resistance.
Since most of the duplicate MRSA isolates were identical,
including these duplicate isolates in the annual antibiogram
rate may impact the calculated rate of susceptibility to other
antimicrobial agents. However, this pattern noted with MRSA
may not apply to other bacteria that develop resistance at a
FIG. 2. Proportion of patients (n  335) with duplicate MRSA
isolates during a 6-year period with identical duplicate antibiogram
phenotypes. The shaded section depicts patient population with iden-
tical isolates, and the clear section represents the populations with
nonidentical duplicate isolates.
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much more rapid rate. The gram-negative pathogens Pseudo-
monas aeruginosa, Acinetobacter baumanii, Klebsiella species,
or Enterobacter species are a few noted examples (9, 19, 21, 23).
Thus, different bacterial species should be evaluated to deter-
mine the appropriate testing and data analysis strategy.
Additional issues in the analysis of duplicate isolates were
recognized as we evaluated these data. There appears to be
little information regarding a consensus for the time period
between testing antimicrobial susceptibility on the same bac-
terial species from the same patient. A certain number of
patients stay in the hospital for extended periods of time, and
duplicate isolates are tested after 3, 4, 7, or 10 days (21, 23). In
this study the laboratory policy was to repeat susceptibility tests
on the duplicate S. aureus isolate from the same patient only
after 7 days. Other laboratories note different time frames,
such as 3 to 10 days, for repeat testing (21, 23). The new
NCCLS guidelines (12) recommend using the first isolate from
a patient in the antibiogram during each analysis period re-
gardless of the total number of isolates tested or changes in
phenotype. The data from the present study show that of 3,227
patients, 917 had duplicate isolates during a 6-year period.
Most patients (91%) with duplicate S. aureus isolates had re-
peat isolates that were all the same; thus, duplicates were
either all MRSA or all MSSA. It was uncommon (6%) for a
patient to be infected with an MSSA and then have an MRSA
strain isolated and even more uncommon (2%) for a patient to
be infected with an MRSA and then have an MSSA strain
isolated. Based on the present study, the NCCLS M39 guide-
line seems to be appropriate for MRSA, since we demon-
strated here that there was little change in phenotype in du-
plicate isolates from the same patient (Fig. 2). However, it may
not apply to other bacterial species that can acquire resistance
within a few days (19, 21, 23). Further studies are needed to
evaluate the impact of duplicate isolates from other bacterial
species on antibiogram data. The detection of new phenotypes
can be used to monitor the development of antimicrobial re-
sistance, which is often used to determine empirical therapy.
Thus, additional information on these issues would help in
developing antibiogram data that can facilitate comparisons
between institutional, regional, and national data and provide
assurance that the data accurately reflect current resistance
patterns.
Analysis of cumulative antibiogram data is valuable in mon-
itoring the development of resistance and in establishing em-
pirical therapy. Removing duplicate isolates is only one factor
in evaluating resistance rates. There is some value in the de-
termination of both isolate-specific and patient-specific data.
The ratio of isolate per patient as proposed by Stelling (42nd
ICAAC) was used in this study to analyze duplicate isolates.
Dividing the number of isolates of each bacterial species by the
number of patients in each analysis period defines this ratio. If
the ratio is 1, then there was one isolate per patient for that
time period. When 1, duplicate isolates were included in the
data. Using this ratio was helpful here in evaluating S. aureus,
but the usefulness of adding this ratio to antibiograms is cur-
rently unknown.
An additional issue is that annual antibiogram data is often
generated electronically, and current laboratory computer sys-
tems are unable to generate this isolate/patient ratio. Labora-
tory information systems do not distinguish the duplicate iso-
lates that occur during the analysis period. Many laboratory
information systems are unable to deal with the complex issue
of duplicate isolates from the same patient and at the same
time detect new phenotypic resistance patterns in consecutive
isolates. An additional concern is that it is difficult to accurately
separate the overall hospital rates for MRSA verses ICU rates
since patients move in and out of these units during a single
hospital stay. At present, the process of identifying and sorting
duplicate isolates and antibiogram types is tedious and re-
quires enormous amounts of time and resources. Therefore,
many hospitals have difficulty following the new NCCLS M39
guideline because of the requisite time and resource commit-
ment. The data analysis in the present study took approxi-
mately 6 to 10 h for each year analyzed and was only evaluating
a single bacterial species. The development of new computer-
ized programs is essential to be able to evaluate duplicate
isolates accurately.
One solution to this issue of duplicate MRSA isolates is to
adopt the alternate testing method to screen the duplicate
isolates by using an oxacillin and a vancomycin agar screen
rather than by performing a comprehensive susceptibility
panel. This strategy was successful in reducing the impact of
duplicate MRSA isolates on the calculated rate of MRSA. It
also resulted in a decreased cost for the laboratory and may be
an option that is useful until more sophisticated computer
programs become available.
Removing duplicate isolates of S. aureus can change an
institution’s antibiogram. This is one of the recommendations
in the new NCCLS document, M39-A (12), designed to im-
prove the quality of antibiogram data. Adherence to the guide-
lines should result in greater utility and standardization of
antibiograms in tracking resistance, improving antibiotic selec-
tion, and comparing data locally, regionally, and nationally.
Thus, it is important to establish within each institution how
duplicate isolates from the same patient are handled and to
acknowledge the effect these duplicate isolate have on annual
antimicrobial susceptibility rates.
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